Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1

American Journal of Gastroenterology

Volumn 107, Issue 11, 2012, Pages 1675-1683

  Jin, Runyan ^a   Cai, Ling ^b   Tan, Ming ^b   McHutchison, John G ^c   Dowling, Thomas C ^a   Howell, Charles D ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; EUROPEAN AMERICAN; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84869491861     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.306     Document Type: Article

References (33)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
2. Fried MW, Shiff man ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med 2002; 347: 975-82.
3. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004; 350: 2265-71. (Pubitemid 38669209)
4. Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7. (Pubitemid 44142464)
5. Hoofnagle JH, Wahed AS, Brown Jr RS et al. Early changes in Hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis 2009; 199: 1112-20.
6. Howell CD, Gorden A, Ryan KA et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol 2012; 56: 557-63.
7. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8. Poordad F, McCone Jr J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
9. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
10. Di Bisceglie AM, Fan X, Chambers T et al. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 2006; 78: 446-51. (Pubitemid 43346894)
11. Howell CD, Dowling TC, Paul M et al. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008; 6: 575-83.
12. Jen JF, Glue P, Gupta S et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65.
13. Snoeck E, Wade JR, Duff F et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62: 699-709. (Pubitemid 44749547)
14. Larrat S, Stanke-Labesque F, Plages A et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47: 124-9. (Pubitemid 36070352)
15. Arase Y, Ikeda K, Tsubota A et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48: 138-44. (Pubitemid 41201504)
16. Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure aft er the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47: 1453-61. (Pubitemid 351702729)
17. Jacobson IM, Brown Jr RS, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81. (Pubitemid 350144761)
18. Brennan BJ, Morcos PN, Wang K et al. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 1209-20.
19. Liu Y, Xu C, Yan R et al. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 832: 17-23. (Pubitemid 43213004)
20. Jin R, Fossler MJ, McHutchison JG et al. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J 2012; 14: 571-80.
21. Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 120, 9.e18.
22. Tian GL, Tang ML, Fang HB et al. Efficient methods for estimating constrained parameters with applications to lasso logistic regression. Comput Stat Data Anal 2008; 52: 3528-42.
23. Girard C, Ravallec M, Mariller M et al. Effect of the 5 ′?non-translated region on self-assembly of hepatitis C virus genotype 1a structural proteins produced in insect cells. J Gen Virol 2004; 85: 3659-70. (Pubitemid 39591873)
24. Herrmann E, Lee JH, Marinos G et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-8. (Pubitemid 36667315)
25. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46: 16-21. (Pubitemid 47171916)
26. Feld JJ, Lutchman GA, Heller T et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139: 154, 62.e4.
27. Balan V, Schwartz D, Wu GY et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005; 100: 299-307. (Pubitemid 40314513)
28. McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006; 26: 389-98.
29. Maynard M, Pradat P, Gagnieu MC et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13: 607-11. (Pubitemid 352016724)
30. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
31. Dixit NM, Layden-Almer JE, Layden TJ et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-4. (Pubitemid 40037156)
32. Thompson AJ, Fellay J, Patel K et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139: 1181-9.
33. Darling JM, Aerssens J, Fanning G et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53: 14-22.